During Market hours on Thursday (24.12.2020):

U.S. stocks posted slight gains in thin trading on Thursday to wrap up the holiday-shortened week.

  • The Dow (Symbol: DIA) went up 0.3%. The S&P 500 (Symbol: SPY) popped 0.4% and the Nasdaq (Symbol: QQQ) rose 0.4%.
  • Nikola (Symbol: NKLA) — Shares of the electric vehicle company shed 8.5% as the stock continued its slide after the announcement of the end of a garbage truck development deal with Republic Services. The stock lost 10.7% on Wednesday. Wedbush Securities called the announcement “a tough pill to swallow for bulls.”
  • Macy’s (Symbol: M) — The retailer slid 3.4% amid weakness in the sector as investors weighed the ongoing impacts of Covid on stores. Kohl’s fell 2%.
  • Marathon Oil (Symbol: MRO) — Shares of the oil company slid 2.6% as the sector gave back some of its gains from the previous session. On Wednesday, the energy sector advanced 2.2%, making it the top-performing S&P sector. Devon Energy and Apache Corporation also came under pressure on Thursday, each declining more than 2%.
  • Apple (Symbol: AAPL) — Shares gained another 0.77%, bringing their gains this week to 4.2%. The advance came after Reuters reported that the tech giant is moving ahead with its automotive efforts, targeting 2024 to produce self-driving vehicles.
  • FuboTV (Symbol: FUBO) — The streaming television stock dropped 16% after LightShed Partners initiated coverage of the company with a sell rating. The stock lost 15.2% on Wednesday, after posting five straight sessions of double-digit percentage gains.
  • Alibaba (Symbol: BABA) — Shares tanked 13.3% on news that the China-based e-commerce giant is the target of a newly launched antitrust investigation by the Chinese government. The primary issue named was a practice that forces merchants to choose one of two platforms, rather than being able to work with both.

 During Premarket hours today – Monday (28.12.2020):

  • AstraZeneca (Symbol: AZN) – The drugmaker said its Covid-19 vaccine candidate is believed by researchers to be effective against a new variant of the virus that has helped drive a spike in cases in Britain. The vaccine is expected to win approval from U.K. regulators this week.

*Any information contained in this article, including any information contained in external third party links, if any, is solely for informational purposes and does not contain, or should not be construed as containing, investment advice or an investment recommendation, or, an offer of or solicitation for any transactions in financial instruments. Past performance does not guarantee or predict future performance. Colmex Pro Ltd does not take into account your personal investment objectives or financial situation and makes no representation, and assumes no liability to the accuracy or completeness of the information provided, nor for any loss arising from any investment based on presented information.